Pyxis Oncology (PYXS) Projected to Post Earnings on Tuesday

Pyxis Oncology (NASDAQ:PYXS) is expected to be announcing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 17, 2025 at 7:00 AM ET.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.01. On average, analysts expect Pyxis Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pyxis Oncology Trading Up 1.4%

Shares of NASDAQ:PYXS traded up $0.06 on Tuesday, hitting $3.87. The company had a trading volume of 677,049 shares, compared to its average volume of 613,226. The business has a 50 day moving average of $2.52 and a 200 day moving average of $1.64. Pyxis Oncology has a 52-week low of $0.83 and a 52-week high of $5.39. The company has a market cap of $239.71 million, a PE ratio of -2.43 and a beta of 1.40.

Hedge Funds Weigh In On Pyxis Oncology

Several large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in shares of Pyxis Oncology in the 2nd quarter worth approximately $40,000. Acadian Asset Management LLC acquired a new position in Pyxis Oncology in the first quarter valued at about $81,000. Bank of America Corp DE grew its stake in Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after acquiring an additional 9,062 shares during the period. Qube Research & Technologies Ltd boosted its position in shares of Pyxis Oncology by 128.4% during the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock worth $113,000 after buying an additional 57,935 shares during the period. Finally, Bridgeway Capital Management LLC boosted its position in shares of Pyxis Oncology by 76.1% during the second quarter. Bridgeway Capital Management LLC now owns 142,295 shares of the company’s stock worth $157,000 after buying an additional 61,500 shares during the period. Institutional investors and hedge funds own 39.09% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on PYXS. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Zacks Research raised Pyxis Oncology from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Finally, Guggenheim lifted their target price on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $8.40.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.